

## **Gesynta Pharma AB Appoints Eva Johnsson as new Chief Medical Officer (CMO) / VP Clinical Development**

**Stockholm, Sweden – April 9, 2025. Gesynta Pharma AB, a clinical-stage pharmaceutical company, today announces the appointment of Eva Johnsson, a proven leader in clinical development, as its new Chief Medical Officer (CMO) and Vice President of Clinical Development.**

Eva Johnsson brings a wealth of experience in clinical drug development and medical affairs, including regulatory approvals and drug commercialization. Eva joins from Grünenthal, where she served as Senior Global Program Lead in the pain and inflammation therapeutic area. Prior to that, she had a long career at AstraZeneca R&D, holding several senior roles with global clinical responsibility. Eva Johnsson is associate professor at the University of Gothenburg.

Gesynta Pharma is preparing a clinical Phase II clinical trial for vipoglanstat, a novel non-hormonal treatment for endometriosis. Affecting one in ten women of reproductive age, this chronic inflammatory disease can cause intense pain and infertility. Vipoglanstat has demonstrated analgesic and anti-inflammatory properties in various preclinical disease models. The upcoming clinical proof-of-concept study will include approximately 190 patients at several clinics across Europe.

Eva Johnsson comments, "Joining Gesynta Pharma as CMO and VP Clinical Development is an exciting new chapter for me. I am eager to work with this talented team, focusing on patient benefits and driving innovation. With a passion for science, I look forward to advancing our pipeline and delivering transformative treatment alternatives for patients suffering from endometriosis, inflammation, and pain."

"Eva's broad experience and deep knowledge in later-stage clinical development will be a valuable addition to our team, strengthening our capabilities for ongoing and future projects," says Patric Stenberg, CEO at Gesynta Pharma. "I look forward to collaborating with her to bring better treatments to patients."

As Eva Johnsson is appointed, Charlotte Edenius, the company's VP Clinical R&D, will shift to a comprehensive strategic role as VP R&D Strategy.

For more information, please contact:

Patric Stenberg, CEO

Tel: + 46 (0)733 83 66 70

E-mail: [patric.stenberg@gesynta.se](mailto:patric.stenberg@gesynta.se)

### **About Gesynta Pharma**

Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1, a key enzyme in inflammatory processes. Gesynta Pharma's research originated at Karolinska Institutet in Sweden.

The lead compound, vipoglanstat, is being developed for the treatment of endometriosis - a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to a severely reduced quality of life and current drug treatments are inadequate for many patients, partly due to troublesome side effects. Vipoglanstat is a non-hormonal, non-opioid, disease-modifying drug candidate that selectively inhibits mPGES-1; it has demonstrated a favorable safety profile and potent inhibition of mPGES-1 in Phase I and II clinical

trials. A preclinical proof-of-concept study in an advanced disease model of endometriosis shows that vipoglanstat significantly reduces endometrial lesions and positively impacts pain-related parameters and well-being. A Phase II clinical trial in patients with endometriosis is expected to start in 2025.

A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase I for the treatment of chronic inflammatory pain.

The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, and other internationally renowned specialist investors. For more information, please visit [www.gesynta.se](http://www.gesynta.se).